Introduction: Cancer immunotherapy may alter tumor biology such that treatment effects can extend beyond radiographic progression. In the randomized, phase III OAK
examine the benefit-risk of atezolizumab treatment beyond progression (TBP).
Methods: Eight hundred fifty patients included in the OAK primary efficacy analysis were evaluated. Atezolizumab was continued until loss of clinical benefit. Docetaxel was administered until Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) disease progression (PD)/unacceptable toxicity; no crossover to atezolizumab was allowed. ORR, PFS, post-PD OS, target lesion change, and safety were evaluated.
Results: In atezolizumab-arm patients, ORR was 16% versus 14% and median PFS was 4.2 versus 2.8 months per immunemodified RECIST versus RECIST v1.1. The median post-PD OS was 12.7 months (95% confidence interval [CI]: 9.3-14.9) in 168 atezolizumab-arm patients continuing TBP, 8.8 months (95% CI: 6.0-12.1) in 94 patients switching to nonprotocol therapy, and 2.2 months (95% CI: 1.9-3.4) in 70 patients receiving no further therapy. Of the atezolizumab TBP patients, 7% achieved a post-progression response in target lesions and 49% had stable target lesions. Atezolizumab TBP was not associated with increased safety risks.
Conclusions: Within the limitations of this retrospective analysis, the post-PD efficacy and safety data from OAK are consistent with a positive benefit-risk profile of atezolizumab TBP in patients performing well clinically at the time of PD.
Introduction
In recent years, cancer immunotherapy (CIT), including anti-programmed death-ligand 1 (PD-L1)/programmed death 1 (PD-1) checkpoint inhibitors, has dramatically shifted cancer treatment paradigms. Atezolizumab is a humanized, engineered monoclonal antibody that targets PD-L1 and prevents PD-L1 interaction with PD-1 and B7.1 receptors. Inhibition of the PD-L1:PD-1 interaction can reinvigorate the suppressed immune system to eliminate cancer cells, and blocking the PD-L1:B7.1 interaction may further enhance immune responses. [1] [2] [3] [4] [5] [6] [7] These effects may result in alterations in tumor biology reflected in anticancer efficacy following initial radiographic disease progression (PD). 2 For this reason, patients in atezolizumab trials have been allowed to continue treatment beyond Response Evaluation Criteria in Solid Tumors (RECIST) v1.1-defined PD (henceforth referred to as PD) as long as they are judged by the investigator to be benefiting clinically and have no unacceptable toxicity.
Although RECIST v1.1-based progression-free survival (PFS) and objective response rate (ORR) are appropriate surrogate endpoints for assessing the survival benefit of some anticancer treatments, they do not always capture the potential overall survival (OS) benefit of checkpoint inhibitor immunotherapies. [8] [9] [10] [11] [12] Based on these observations in patients with metastatic melanoma who were treated with ipilimumab, immune-related response criteria were developed and more recently, RECIST-based modified criteria (immune RECIST and immune-modified RECIST [imRECIST]) were introduced. [13] [14] [15] Discordance between radiographic endpoints and OS was also observed with anti-PD-L1/ PD-1 agents, particularly when used as monotherapy in patients with NSCLC unselected for PD-L1 expression. 18 Similar discordance was observed in the randomized POPLAR phase II trial. 17 These observations suggest that atezolizumab can have beneficial post-progression treatment effects and provide a rationale for allowing treatment beyond progression (TBP) for patients who are performing well clinically. Nevertheless, further characterization of this patient subgroup is needed to better understand the discordance between endpoints and determine the efficacy and safety of TBP. In this analysis, patients from the primary population of OAK who were treated with atezolizumab TBP were evaluated to characterize efficacy, as measured by radiographic changes in target lesions and post-PD OS, and for safety before and after PD. For context, post-PD OS among atezolizumab-and docetaxel-arm patients who switched to other nonprotocol anticancer therapy (NPT) at PD or received no subsequent anticancer treatments was also evaluated.
Materials and Methods

Study Design and Patients
OAK was a randomized, open-label, international phase III study comparing the efficacy and safety of atezolizumab versus docetaxel in patients with locally advanced or metastatic (stage IIIb or IV) squamous or nonsquamous NSCLC who had progressed after one to two previous chemotherapy regimens (including one or more platinum-based therapies). Patients with EGFR mutations or an ALK fusion oncogene were required to have received previous tyrosine kinase inhibitor therapy. Details on patient eligibility criteria, stratification, and randomization between study treatment arms were described previously. , and patient's written consent to defer any standard treatment options that may exist in favor of continuing atezolizumab treatment at the time of initial progression). Patients could continue atezolizumab TBP if additional subsequent tumor assessments indicated PD, as long as the criteria above continued to be met. Docetaxel was administered until PD or intolerable toxicity and treatment with docetaxel beyond radiographic PD was not allowed. After treatment discontinuation, patients in both arms were followed for OS and subsequent NPT every 3 months. No crossover from docetaxel to atezolizumab was allowed.
Treatment and Assessments
Tumor evaluations, per RECIST v1.1 (both arms) and imRECIST 15 (atezolizumab arm only) as assessed by the investigator, were performed at baseline, then every 6 weeks until week 36 and every 9 weeks thereafter until PD. If patients experienced progression after 36 weeks and continued atezolizumab TBP, a follow-up assessment was performed 6 weeks (±2 weeks) after the initial progression before converting to the every-9-weeks schedule. Patients receiving atezolizumab TBP continued tumor assessments until treatment discontinuation and were followed for survival every 3 months after treatment discontinuation.
Outcomes
Patients in the atezolizumab arm were evaluated for ORR and PFS per imRECIST and results were compared with ORR and PFS per RECIST v1.1 criteria. Continuation of docetaxel treatment was not allowed beyond progression; therefore, ORR and PFS in the docetaxel-arm patients were not evaluated per imRECIST. Patients in both atezolizumab and docetaxel arms who experienced PD were evaluated for OS from the time of PD. Patients who continued atezolizumab TBP were also evaluated for change in target lesions (sum of longest diameters [SLD] post-PD versus baseline reset to the measurement at the time of PD). Only target lesions from the original baseline per RECIST v1.1 were evaluated and the analysis did not represent a second complete RECIST v1.1 response evaluation that could have allowed reselection of new target or nontarget lesions. This analysis is consistent with those previously reported for postprogression radiographic changes. 19 Safety was assessed in patients who continued atezolizumab TBP. The incidence, nature, and severity of adverse events (AEs) and laboratory abnormalities were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. AEs were reported from the time of first dose to 30 days following treatment discontinuation, except for serious treatment-related AEs that were reported throughout survival follow-up. Pre-and post-PD AEs were summarized. Pre-PD AEs were defined as those with onset dates after the first treatment dose and before the date of first PD. Post-PD AEs were defined as events with onset dates after the first treatment dose on or after the date of first PD, and included worsening severity of an ongoing AE that had initial onset during the pre-PD period.
Statistical Analysis
Demographic and baseline disease characteristics were summarized according to the treatment received after PD. Baseline measurements from the last available assessment obtained before cycle 1, day 1 visits were used unless otherwise stated. Changes in several disease characteristics at the time of PD relative to the baseline were summarized.
ORR and PFS analyses per imRECIST were performed as described previously. 15 The post-PD survival analyses performed in this study were descriptive. OS post-PD was defined as the difference in time from the date of PD to the date of death due to any cause. Data for patients not reported as dead at the time of analysis were censored at the date they were last known to be alive. The Kaplan-Meier approach was used to estimate the median OS post-PD and construct survival curves; the Brookmeyer-Crowley methodology was used to estimate 95% CIs for the median OS. PFS and ORR were defined and analyzed using the same methodologies as in the primary analysis. 18 
Results
Population
As previously reported, the primary analysis of OAK showed an OS benefit with atezolizumab over docetaxel in the intention-to-treat population (the first 850 patients enrolled), with benefit observed across different levels of PD-L1 expression on tumor cells (TCs) or tumor-infiltrating immune cells (ICs). 18 The same population (N ¼ 850) was evaluated here for TBP; 425 patients were randomized to each treatment arm (Fig. 1 ).
Demographic and baseline characteristics were well balanced between treatment arms. 18 At the time of data cutoff (July 7, 2016), with a median follow-up of 21 months, 332 patients (78%) in the atezolizumab arm and 290 (68%) in the docetaxel arm had experienced PD. Examination of PD patterns indicated that a similar proportion of patients in each arm progressed at sites of existing disease (target lesions or nontarget lesions) and new lesions (Supplemental Table 1 ). Remaining patients who did not experience PD included those who continued treatment with a response or stable disease, or discontinued treatment and scans for reasons other than radiographic PD (Supplemental Table 2 ). Although fewer patients in the docetaxel arm than in the atezolizumab arm experienced PD, the docetaxel arm had a higher proportion of patients withdrawing from treatment before PD.
ORR and PFS Per imRECIST
Patients in the atezolizumab arm had 2% higher ORR per imRECIST than RECIST v1.1 (16%, 95% CI: 12-20 versus 14%, 95% CI: 11-17, respectively), and 1.4 months longer median PFS per imRECIST than RECIST v1.1 (4.2 months, 95% CI: 3.9-4.6 versus 2.8 months, 95% CI: 2.6-3.0, respectively).
Post-PD Treatments
Among the 332 atezolizumab-arm patients who had PD, 168 (51%) continued atezolizumab as TBP, 94 (28%) instead received subsequent NPT, including 7 (2%) who received immunotherapy and 70 (21%) did not receive subsequent anticancer therapy. Among the 290 docetaxel-arm patients with PD, 167 (58%) received subsequent NPT, including 65 (22%) who received immunotherapy, and 123 (42%) did not receive subsequent anticancer therapy (Fig. 1 ). Supplemental Table 3 shows NPT use among all patients who had PD. Patients who received immunotherapy could have received additional NPTs.
Survival and Response With TBP
Among patients who experienced radiographic PD, the median OS post-PD was 8.6 months (95% CI: 7.0-9.9) in the atezolizumab arm versus 6.4 months (95% CI: 5.3-7.6) in the docetaxel arm. At 18 months post-PD, 26% of patients in the atezolizumab arm versus 18% in the docetaxel arm were alive ( Fig. 2 ; Supplemental Table 4 ).
To aid interpretation of post-PD OS data among the nonrandomized subgroups of atezolizumab-arm patients based on subsequent therapy received, baseline characteristics and clinical status at PD were examined. Baseline characteristics were relatively comparable between all three subgroups, with numerically more women, fewer prior therapies, and numerically higher PD-L1 expression (1% or more on TC or IC) among patients continuing atezolizumab TBP than those switching to NPT at PD, and a higher proportion with ECOG PS 1 in the subgroup that received no subsequent anticancer therapy ( Table 1) . Comparison of changes in potential prognostic clinical factors from baseline to the time of PD revealed that patients continuing atezolizumab TBP had a higher incidence of multiple brain metastases and lower incidence of worsened ECOG PS than those who switched to subsequent NPTs (Table 1) . Weight changes and albumin decreases were small except among patients who did not receive any treatment after PD. A slightly lower percentage increase in target lesions at the time of PD relative to baseline was observed in patients continuing atezolizumab TBP, but numbers were comparable to those in patients who did not continue. Additionally, patients continuing atezolizumab TBP had a similar ORR and shorter median PFS relative to patients who switched to a different therapy after PD (Table 1) .
Patients in the atezolizumab TBP cohort received atezolizumab treatment for a median of 3 cycles (range, 1-30 cycles) and 2.1 months (range, 0.7-20.7 months) pre-PD and for a median of 3 cycles (range, 1-34 cycles) and 1.5 months (range, 0-22.4 months) post-PD. Of 168 patients, 17 (10%) were treated for 12 months or longer post-PD. The best change in SLD of target lesions following PD was examined in patients receiving atezolizumab post-PD, among whom 122 had one or more post-PD target lesion measurement. Relative to the baseline reset at the time of PD, 7% of patients (12 of 168) had a subsequent response in target lesions (30% or more reduction from new baseline at PD) and 49% (83 of 168) had stable target lesions (best change between þ20% and À30%) post-PD (Fig. 3A) . Although the two patients with the greatest post-PD target lesion shrinkage had PD-L1-high tumors (TC3 or IC3), patients from all PD-L1 subgroups showed stability or a decrease (Fig. 3A) . Spider plots of patients with post-PD response, stable disease, and PD in target lesions are shown in Figures 3B through 3D . Of the target lesion responders, 42% (5 of 12) had a 30% or more decrease in target lesions relative to initial PD at 24 weeks or later after the initial PD, three of whom had a 30% or more decrease at 1 year or later after initial PD. Two patients with post-PD target lesion response experienced subsequent new lesions and one patient with post-PD target lesion response experienced subsequent progression in nontarget lesions, with all three of these progression events occurring more than 36 weeks from the time of initial PD (Fig. 3B) . Six of the 12 patients had an initial best response of PD, and only 1 patient had a partial response. However, 7 of 12 patients were still alive at the time of the analysis, and 7 had OS of 20 months or longer. Patients with target lesions that were stable post-PD, representing the majority of TBP patients, had a variety of response patterns that included long-term stabilization of target lesions and those that developed further progression after one or more additional post-PD assessments (Fig. 3C) . Patients with further PD in target lesions after initial progression tended to discontinue TBP quickly afterwards (Fig. 3D) .
Evaluation of post-PD OS in atezolizumab-arm patient subgroups according to subsequent therapy revealed a median post-PD OS of 12.7 months (95% CI: 9.3-14.9) in patients continuing atezolizumab TBP, with 37% surviving for 18 months or longer post-PD. Similar post-PD OS and 18-month survival rates were observed in this subgroup when the aforementioned 12 patients with target lesion response were excluded (Supplemental Table 4 ). Patients who switched to other NPTs lived a median of 8.8 months (95% CI: 6.0-12.1) post-PD, and those who did not receive subsequent therapy lived a median of 2.2 months (95% CI: 1.9-3.4). The 18-month survival rates were 20% and 9% in patients who received subsequent anticancer NPT or no anticancer therapy, respectively ( Fig. 4A ; Supplemental Table 4 ). In the docetaxel arm, patients switching to NPT lived a median of 9.6 months (95% CI: 7.9-11.8) post-PD, with shorter OS observed in patients not receiving subsequent therapy (3.7 months [95% CI: 2.7-4.0]). The 18-month survival rate post-PD was 25% and 8%, respectively ( Fig. 4B ; Supplemental Table 4 ).
OS With Nonprotocol Immunotherapy as Subsequent Treatment
We further evaluated both atezolizumab-and docetaxel-arm patients by the nature of the subsequent NPT received, that is, immunotherapy versus nonimmunotherapy. Docetaxel-arm patients treated with subsequent immunotherapy had a post-PD median OS of 17.3 months (95% CI: 13.9-19.6; n ¼ 65) versus 7.5 months (95% CI: 6.0-8.2; n ¼ 102) in patients treated with nonimmunotherapy NPT. The 18-month survival rate post-PD was 42% and 12%, respectively ( Fig. 4C ; Supplemental Table 4 ). Far fewer atezolizumab-arm Table 4 ).
Safety Profile of Atezolizumab TBP
The safety profile of atezolizumab TBP in patients with AE onset before and after PD revealed that allgrade and grade 3-4 AE frequencies were similar during the post-PD period versus the pre-PD period (Fig. 5A ). Similar observations were made for atezolizumab treatment-related all-grade and grade 3-4 AEs (Fig. 5B) . Serious AEs regardless of causality were numerically higher post-PD, and rates of AEs of special interest for this drug class showed similar rates preand post-PD (Fig. 5A) . No apparent association between immune-related AEs (pre-or post-PD) and post-PD response was observed and the post-PD safety of atezolizumab was consistent with the known safety profile of atezolizumab in patients with NSCLC.
Discussion
The goal of this analysis was to characterize postprogression outcomes in patients in the OAK trial to 1) better understand the discordance between radiographic endpoints and OS with atezolizumab in the second-/ third-line NSCLC setting, and 2) evaluate the benefit-risk of continuing atezolizumab TBP versus discontinuing in favor of other treatment options. Evaluation of radiographic endpoints per imRECIST in the atezolizumab arm was an exploratory objective of the study with the goal of investigating the frequency of unconventional response patterns associated with immunotherapy. Although not prespecified, analyses focusing on safety and efficacy in the post-PD treatment period were performed based on the disconnect between OS and PFS benefit observed in OAK and POPLAR studies of atezolizumab monotherapy as well as other studies of PD-1 checkpoint inhibitors in certain treatment settings. 17, 18, [20] [21] [22] They are intended to contribute to evolving knowledge on checkpoint inhibitor patterns of response and progression, as recently described in multiple other tumor types. Evaluation of postprogression effects is relevant to CIT agents because of the potential for nonclassical progression patterns that may be driven by increased immune infiltration of the tumor, delayed response, and impact on OS that surpasses effects reflected by PFS or ORR, as was shown in OAK. 18, 23 Post-progression prolongation of survival (PPPS), a term implying continued benefit in OS after PD and originally applied to continuation of EGFR inhibitor therapy, provides a rationale for atezolizumab TBP in clinical trials. 24 Interest in the potential role of immunotherapy TBP is broad-based, as shown by a recent publication authored by the U.S. Food and Drug Administration, in which they acknowledge confusion among patients and treating physicians, and recommended prospective studies. 23 To date, analyses of post-PD effects of atezolizumab in metastatic urothelial carcinoma, nivolumab in renal cell carcinoma and melanoma, and anti-PD-1 agents in metastatic NSCLC and melanoma have been reported. [25] [26] [27] [28] [29] [30] Whereas ORR was only slightly increased per imRECIST versus RECIST v1.1, median PFS was 1.4 months longer per imRECIST criteria. These results are similar to those seen in POPLAR and other atezolizumab trials. 15 Considering that the analysis of endpoints per imRECIST describe radiographic efficacy both before, and (in some cases) after PD, we also performed analyses specifically focused on post-PD radiographic changes in the atezolizumab TBP subgroup. The post-PD analysis revealed that most patients experienced stability or a response in target lesions after initial PD, and in rare cases durable responses were observed. Although the analysis of change in post-PD target lesions did not account for the potential growth of new lesions that contributed to the initial PD assessment, development of additional new lesions or progression in nontarget lesions occurred in only 3 of the 12 post-PD target lesion responders. These events occurred more than 36 weeks after initial progression. In aggregate, the post-PD tumor assessment results suggest that atezolizumab TBP can provide continuing antitumor effects that slow or even abrogate tumor growth. Although substantial post-PD tumor shrinkage was rare, consistent with the small increase in ORR per imRECIST relative to RECIST v1.1, the median post-PD OS was 12.7 months in patients who continued atezolizumab TBP. Although these patients were selected for performing well clinically at the time of PD (that is, no decrease in PS, weight loss, or severe toxicity despite PD) when compared with a historical survival outcome of 5 to 10 months seen with chemotherapy in the second-/third-line setting, these data suggest that patients who received atezolizumab TBP had relatively favorable outcomes. 31, 32 The similar post-PD OS observed in the atezolizumab TBP subgroup when post-PD target lesion responders were excluded suggests that the OS outcomes were not driven solely by patients experiencing post-PD response. Although the post-PD OS seen in patients who switched to NPT was shorter (8.8 months), interpretation of relative outcomes must consider that these groups are not formally comparable because there was no controlled randomization to continue atezolizumab versus switching to different therapy. The criteria for atezolizumab TBP, including investigator-assessed continued clinical benefit, introduces bias. Additionally, patients continuing atezolizumab TBP had better clinical status at the time of PD than patients who switched therapies. However, the fact that these patients were clinically well enough to start subsequent NPT suggests that they were likely not experiencing rapid clinical deterioration. The short post-PD OS in patients who did not receive further therapy post-PD (2.2 months) likely reflects an inferior clinical status associated with ineligibility for further treatment. Atezolizumab was well tolerated and reported in OAK and other trials to have a favorable safety profile versus docetaxel. 17, 18 Atezolizumab TBP did not appear to be associated with increased safety risk based on similar rates of treatment-related AEs (including high-grade) and AEs of special interest. Patients who continued atezolizumab TBP were required to not have experienced unmanageable treatment-related toxicity, which likely decreased the risk of post-PD immune toxicities. A numerically higher rate of post-PD serious AEs regardless of causality was observed which may reflect eventual worsening disease symptoms that would have prohibited continuation of atezolizumab had they occurred before PD.
Among the docetaxel-arm patients, post-PD OS was longer in those who received subsequent NPT versus those who stopped therapy. Because docetaxel patients were required to discontinue study treatment at PD, the effect of continued docetaxel TBP could not be evaluated; thus, it remains unclear whether PPPS is specific to atezolizumab or other immunotherapies. The prevalence of patients who discontinued treatment post-PD was greater for the docetaxel arm compared with the atezolizumab arm, which may reflect the availability of more treatment options, including third-line docetaxel, following atezolizumab treatment at the time the trial was conducted. Consistent with the known benefit of recently approved PD-L1/PD-1 inhibitors in this treatment setting, post-PD survival in docetaxel-arm patients switching to immunotherapy as NPT at progression (17.3 months) was long in the context of historical second line or beyond NSCLC setting outcomes. 31, 32 Although these data suggest that immunotherapy crossover strengthened the OS curve of the control arm, the frequency or magnitude of OS benefit observed in these patients was not large enough to offset the robust OS benefit seen with atezolizumab treatment in the primary analysis. 18 Furthermore, only 65 of 425 docetaxel-arm patients received post-PD immunotherapy, and they may represent a select group of patients with an improved prognosis, precluding any conclusion regarding optimal treatment sequence. In addition, while the seven atezolizumab-arm patients who switched to another immunotherapy as NPT after PD also had long post-PD OS, the small sample size of this group made drawing conclusions difficult.
This analysis was based on a large phase III study with well-balanced treatment arms and a homogenous patient population at baseline, thus providing a robust dataset. Fifty percent or more of the atezolizumab-arm patients who experienced PD continued atezolizumab TBP; the OS data were mature (minimum follow-up of 19 months). Limitations of this analysis primarily stem from its retrospective nature and inherent bias associated with lack of randomization of atezolizumab-arm patients among different subgroups post-PD, thus ruling out any formal and meaningful hypothesis testing of survival benefit with atezolizumab TBP relative to switching to alternative therapy. The post-PD subgroups are incomparable because patients in the atezolizumab TBP subgroup were already experiencing clinical benefit from treatment per investigator assessment before PD, a criterion that was not applicable to patients who switched to NPT, thus introducing bias. Results from these analyses are therefore descriptive and limit any conclusions that can be drawn based on comparisons between post-PD groups. Lastly, whether the PPPS benefit with atezolizumab is related to TBP or due to a lingering effect of PD-L1 blockade that alters antitumor biology even following atezolizumab discontinuation remains to be addressed. A favorable PFS after 1 year of treatment was seen in nivolumab-treated patients with NSCLC who showed stable disease or better and were subsequently randomized to continue rather than discontinue therapy, consistent with the hypothesis that continued therapy may be important for continued benefit. 33 Considering these strengths and limitations, the aggregate efficacy and safety data for atezolizumab TBP showed here suggest a positive benefit-risk profile in previously treated patients with NSCLC who are judged by their treating physician to be performing well clinically at the time of RECIST v1.1 progression. These findings are consistent with prior conclusions that RECIST v1.1-defined endpoints may not adequately describe clinical benefit from atezolizumab in the 2Lþ NSCLC treatment settings, and with conclusions from other TBP analyses for atezolizumab in metastatic urothelial carcinoma as well as with TBP analyses for PD-1 inhibitors in renal cell carcinoma, NSCLC, and melanoma. [25] [26] [27] [28] [29] [30] Confirmation of these findings will require a prospective trial in which patients are randomized to continue or stop atezolizumab at the time of PD.
